Phase 2 Trial of Adoptive Cell Therapy with TILs Plus IL-2
Phase 2
170
about 14 years
18–72
1 site in MD
What this study is about
This trial is testing a new treatment for melanoma. It involves taking cells from your tumors, growing them in the lab, and then returning them to you. Researchers are also investigating if adding pembrolizumab might improve this therapy's effectiveness.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive young TIL
- 2.Take Aldesleukin
- 3.Take Cyclophosphamide
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
aldesleukin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Response rate
Secondary: Frequency and severity of treatment-related adverse events, Objective response rate (ORR), progression free survival (PFS) and safety (Cohort 3, Arm 3), Overall survival, Overall survival (Cohort 3, Arm 3)
Oncology